Xencor, Inc last reported quarterly results on Oct 26, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $116.5 million (+454.9% year over year) and diluted EPS of $0.50. It usually reports 8–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 26, 2026
26 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
117
+454.9%
|
39
+754.3%
|
0.50
+725.0%
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
51
+17.5%
|
-22
+29.5%
|
-0.29
+29.3%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
5
-86.2%
|
-129
-166.3%
|
-1.71
-159.1%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
28
-46.5%
|
-7
+85.4%
|
-0.09
+85.7%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
21
+18.0%
|
-6
+87.0%
|
-0.08
+88.9%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
44
+82.4%
|
-31
+54.2%
|
-0.41
+62.4%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
33
+104.6%
|
-48
+34.1%
|
-0.66
+45.0%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
53
+3.6%
|
-46
-74.2%
|
-0.62
-44.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XNCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1326732
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.